
Cheat meals taste so good — new evidence suggests they are so bad for your body
New research confirms that just two days of eating a high-fat diet can compromise critical immune cells in the gut and weaken the intestinal barrier, suggesting the impact of our daily dietary choices is more immediate than previously believed.
3 Consuming a high-fat diet led to the rapid suppression of specialized immune cells in lab mice.
Home-stock – stock.adobe.com
Advertisement
Published this month in the journal Immunity, the research followed mice fed a regular diet, a high-fat diet and specialized diets enriched with saturated and unsaturated fats.
The high-fat diet led to the rapid suppression of specialized immune cells called ILC3s, which produce a protective substance called interleukin-22 (IL-22). This suppression is disastrous for the digestive system.
Within the gut, IL-22 typically shields the intestinal barrier by generating protective elements that prevent bacteria, toxins, undigested food particles and inflammatory pathogens from breaching the bloodstream.
Advertisement
When a high-fat diet limits the production of IL-22, that intestinal barrier becomes more permeable, a condition known, inelegantly, as 'leaky gut.'
While not a formal diagnosis, leaky gut is known to cause bloating, constipation, indigestion, acid reflux and potentially intestinal pain.
What's worse, when toxins leak beyond the gut, they trigger widespread inflammation, leading to issues like skin problems, brain fog, anxiety, depression, cardiovascular stress and even fertility challenges.
Advertisement
'The more saturated fats we eat, the more inflammation that builds up,' said study author Cyril Seillet from The Walter and Eliza Hall Institute of Medical Research in Australia. 'This inflammation build-up is initially silent, remaining hidden in our bodies until years later, where it can present as chronic inflammation.'
Seillet and his team discovered that different fats have wildly different effects on overall gut health.
They found that unsaturated fatty acids, found in olive oil and avocados, helped support normal IL-22 production and gut barrier function.
3 The study authors discovered that different fats have wildly different effects on overall gut health.
Cell Press
Advertisement
In contrast, saturated fatty acids, present in palm oil, butter and fatty animal meat, deliver a one-two punch by seriously hindering immune cell function and increasing intestinal inflammation.
After just two days on high-fat diets, researchers observed that certain subtypes of ILC3 immune cells already exhibited reduced IL-22 production. A week into the high-fat diet, all ILC3 subtypes were compromised.
Further, within a week on the high-fat diet, the gut microbiome had rapidly shifted, exhibiting a decline in beneficial bacteria that produce short-chain fatty acids and a proliferation of harmful bacteria.
Using specialized equipment, the research team discerned that one week on a high-fat diet correlated to 'leakier' mice intestines, a permeability that allowed more potentially dangerous substances to pass through.
There is a bit of silver (intestinal) lining to be found in this latest batch of research — the gut-compromising consequences of a high-fat diet aren't permanent.
The research team found that after resuming a regular diet, gut function improved after just two days and returned to normal after seven days. This quick correction suggests dietary interventions could rapidly restore gut health.
3 Blessedly, researchers found that the gut-compromising consequences of a high-fat diet aren't permanent.
littlepigpower – stock.adobe.com
Advertisement
In addition, researchers found that saturated and unsaturated fatty acids are processed in entirely different ways.
Saturated fats are processed through a pathway called fatty acid oxidation, which impairs immune function, while unsaturated fats like oleic acid form protective lipid droplets in the cells, helping to maintain proper immune responses.
To demonstrate how the processing of these fats influences intestinal inflammation, the research team induced colitis in the mice. The mice fed saturated fats showed greater tissue damage than those that ate unsaturated fats or adhered to a regular diet.
Advertisement
Results were similar when the team exposed isolated human immune cells to different fatty acids. Essentially, unsaturated fats support immune function while saturated fats suppress IL-22 production.
Researchers believe these rapid and profound changes in gut health could explain why people experience digestive discomfort when they veer from their regular diets during the holidays or on vacation.
Conversely, these results serve to explain why diets rich in olive oil and unsaturated fats, such as the lauded Mediterranean diet, are associated with lower levels of inflammation and improved gut health.
Advertisement
How important is gut health? Research reports that Parkinson's disease may begin in the gut.
A 2022 study from New York's Clarkson University even found a possible link between a person's gut health and personality.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
4 days ago
- Business Wire
Genascence Announces U.S. Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to GNSC-001 for Knee Osteoarthritis (OA)
PALO ALTO, Calif.--(BUSINESS WIRE)--Genascence Corporation ('Genascence'), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA). GNSC-001 is a genetic medicine – a recombinant adeno-associated viral vector expressing an optimized human interleukin-1 receptor antagonist (IL-1Ra), a naturally occurring protein that blocks IL-1 signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and cartilage destruction. GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single intra-articular injection into the affected joint. 'GNSC-001 is the first IL-1 inhibitor for OA that has been shown to generate IL-1Ra expression levels that maintain therapeutic thresholds long-term following a single administration to inhibit pathogenic IL-1. The FDA RMAT designation for GNSC-001 underscores the strength of the clinical data to date, recognizing its potential to transform the treatment paradigm for OA,' said Thomas Chalberg, Ph.D., founder and CEO of Genascence. 'With the RMAT designation for GNSC-001, we look forward to working closely with the FDA as we seek to accelerate late-stage clinical development of GNSC-001 so we can bring a new treatment option to people suffering from this incapacitating, disabling disease.' To date, GNSC-001 has been studied in two human clinical trials. The first-in-human Phase 1 study (NCT02790723) was a single-center, open-label, dose-escalation design in nine participants with knee OA. The DONATELLO Phase 1b clinical trial (NCT05835895) is a double-blind, placebo-controlled dose-ranging study designed to evaluate the safety, tolerability, and pharmacodynamics of a single intra-articular injection of GNSC-001 in patients with OA of the knee that enrolled 67 participants at 10 centers across the U.S. The RMAT designation is a special FDA program aimed at speeding up the development and review of promising cell and gene therapies under the 21 st Century Cures Act. The FDA grants RMAT designation to drug candidates that show potential to treat, modify, reverse, or cure serious or life-threatening diseases and address unmet medical needs. The FDA's RMAT designation offers sponsor companies all the benefits of the fast track and breakthrough therapy designation programs. In addition, RMAT designation provides accelerated development and review pathways for regenerative medicine products, including early and intensive FDA guidance, potential eligibility for accelerated approval and priority review, and the possibility of rolling review. The U.S. Food and Drug Administration (FDA) granted GNSC-001 Fast Track designation in the fourth quarter of 2024. Earlier this year, Genascence completed a successful meeting with the FDA on the design of the Phase 2b/3 clinical trial of GNSC-001 focused on clinical efficacy and plans to initiate the Phase 2b/3 study in 2026. The DONATELLO clinical trial was supported by a $12 million award from the California Institute for Regenerative Medicine (CLIN2-14265). About Osteoarthritis (OA) of the Knee Osteoarthritis (OA) is a progressive joint disease that is a leading cause of disability. It is characterized by destruction of cartilage and structural changes in bone within the joint, which contribute to pain and loss of joint function. Osteoarthritis affects more than 30 million Americans and is increasing as a result of the aging population and increasing prevalence of obesity. Osteoarthritis represents a major economic burden, owing to direct medical costs and loss of productivity. Each year, millions of patients are treated for knee OA with NSAIDs, opioids, and steroid injections into the knee to manage their knee pain. There are no currently available therapies known to alter or slow down OA progression. About Genascence Corporation Genascence, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, is developing life-changing treatments for highly prevalent conditions affecting millions of people. The company was founded in 2017 with technology licensed from three leading U.S. research institutions: Mayo Clinic, University of Florida, and NYU Langone Health. Headquartered in Palo Alto, California, Genascence's founders and leadership team have deep experience in the design, development, and manufacturing of successful gene therapies and biological medicines. For more information, please visit
Yahoo
5 days ago
- Yahoo
Otsuka to acquire Cantargia's CAN10 for autoimmune diseases
Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme, an antibody in development as a drug candidate for autoimmune diseases. CAN10 targets interleukin-1 receptor accessory protein (IL1RAP) with potent inhibitory effects on pro-inflammatory cytokines within the interleukin 1 (IL-1) superfamily — IL-1, IL-33 and IL-36 — which are associated with various inflammatory or autoimmune diseases. Cantargia will receive a $33m upfront cash payment and up to an additional $580m in milestone payments, along with double-digit tiered earn-out payments from worldwide product sales. The transaction is subject to customary closing conditions and regulatory approval, with expectations set for completion in the third quarter of 2025. Otsuka Pharmaceutical president and representative director Makoto Inoue stated: "Otsuka Pharmaceutical is expanding its research and development pipeline in the field of autoimmune diseases by leveraging the antibody drug platform of our US subsidiary, Visterra, and the low-molecular-weight drug discovery platform of our US subsidiary Jnana Therapeutics. 'This will further expand and accelerate our research and development portfolio targeting various pathways associated with autoimmune diseases, enabling us to contribute to the lives of more patients." Otsuka Pharmaceutical will take full responsibility for developing and commercialising CAN10 across the globe. This entails directing all future development activities, seeking regulatory approvals, as well as exclusively managing manufacturing and sales operations worldwide. Otsuka Pharmaceutical also gains access to 3G5, a backup antibody. CAN10 is currently in a Phase I clinical trial. Cantargia interim CEO Damian Marron stated: 'This is a transformative transaction for Cantargia, and we hope for millions of patients suffering from severe immune-inflammatory disorders. 'We are delighted that the strong potential of our CAN10 anti-IL1RAP antibody has been recognised by Otsuka Pharmaceutical. It demonstrates confidence in the strength of our world-leading position in IL1RAP biology and antibodies and will allow us to drive forward our platforms and programs in oncology and other diseases.' "Otsuka to acquire Cantargia's CAN10 for autoimmune diseases" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
5 days ago
- Yahoo
LEO Pharma secures rights to Boehringer's Spevigo for $105m
Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim's psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening its portfolio ahead of a possible public listing in 2026. The transaction will see LEO gain the exclusive global licence for Spevigo, taking control of commercialisation and development rights. The full terms of the deal were not disclosed as both companies are privately owned, but LEO confirmed it is in line for milestone payments and royalties. The deal is expected to close in the second half of 2025. Spevigo is approved in the US, Japan, China and most European countries to treat generalised pustular psoriasis (GPP) flares, a rare but severe dermatological disease that can be fatal. It has also been approved in expanded indications in GPP in certain territories. LEO's new asset is a monoclonal antibody that blocks the activation of the interleukin-36 (IL-36) receptor - a key signalling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases. Indeed, GPP may not be the ceiling for Spevigo – LEO said there is an 'opportunity to investigate the potential of Spevigo in additional skin conditions with high unmet medical need in which IL-36 is implicated'. LEO calls Spevigo 'the flagship dermatology product' of Boehringer Ingelheim, though the drug's sales have not been publicly disclosed. Comparing sales from other drugs is tricky because Spevigo is the only US Food and Drug Administration (FDA)-approved treatment specifically for GPP. Boehringer Ingelheim's head of human pharma Shashank Deshpande said: 'Spevigo holds a significant promise, and ensuring it reaches its full potential requires continued focus and expertise in medical dermatology. With over six decades of singular dedication to this field, LEO Pharma is exceptionally well-positioned to build on the strong foundation we've laid.' Adding Spevigo to its portfolio represents a strengthening of assets for dermatology specialist LEO. The Danish drugmaker has been building its pipeline amid reports it is planning an initial public offering (IPO) next year. Christophe Bourdon, who was appointed CEO in 2022 and tasked with turning the fortunes of the company around, has made no secret of public listing plans. In an interview with Bloomberg yesterday [14 July], Bourdon said market conditions and shareholders' wishes will decide the best timing for an IPO. The deal with Boehringer Ingelheim marks the second time LEO has signed a licensing agreement with a big pharma company in 2025. In January, Gilead Sciences offered a potential $1.7bn for LEO's preclinical STAT6 research programmes, which the dermatology company agreed to. As part of the deal, LEO received $250m in an upfront payment, boosting its cash on hand. "LEO Pharma secures rights to Boehringer's Spevigo for $105m" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio